Respiratory outcome in cystic fibrosis patients given successively mucolytic agents for 1 year and dornase alfa for 1 year;Evolution respiratoire de patients atteints de mucoviscidose traites par mucofluidifiants puis par dornase alfa

Archives de Pediatrie

Volumn 5, Issue 4, 1998, Pages 371-377

  Derelle, J ^a   Bertolo Houriez, E ^a   Marchal, F ^a   Weber, M ^b   Virion, J M ^c   Vidailhet, M ^a  

^a HÔPITAL D ENFANTS   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c Hopital Marin   (France)

Author keywords

Child; Cystic fibrosis; Dornase alfa; Expectorants; Lung volume measurements; Recombinant proteins

Indexed keywords

AMBROXOL; DORNASE ALFA; MUCOLYTIC AGENT;

ALGORITHM; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; NEBULIZATION; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032054849     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(98)80022-5     Document Type: Article

References (25)

1. 1 Rommens JM, Iannuzzi MC, Kerem BS, Drum ML, Melmer G, Dean M et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989 ; 245 : 1059-65
2. 2 Cantin A. Cystic fibros is lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995 ; 151 : 939-41
3. 3 Puchelle E, Jacquot J, Beck G, Zahm JM, Galabert C. Rheological and transport properties of airway secretions in cystic fibrosis: relationships with the degree of infection and severity of the disease. Eur J Clin Invest 1985 ; 15 : 389-94
4. 4 Moss RB. Pathways to inflammation in cystic fibrosis. Pediatr Pulmonol 1996 ; (suppl 13) : 158-9
5. 5 Shak S. RhDNase, bases scientifiques, clonage et production. Arch Pédiatr 1995 ; 2 : 666-9
6. 6 Armstrong JB, White JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950 ; ii : 739-45
7. 7 Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990 ; 87 : 9188-92
8. 8 Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human Dnase I on sputum in patients with cystic fibrosis. Thorax 1996 ; 51 : 119-25
9. 9 Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozime study group. N Engl J Med 1994 ; 331 : 637-42
10. 10 Kirchner KK, Wagener JS, Kahn TZ, Copenhaver SC, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Care Med 1996 ; 154 : 1426-9
11. 11 Zahm JM, Girod de Bentzmann S, Deneuville E, Perrot-Minnot C, Dabadie A, Pennaforte F et al. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Resp J 1995 ; 8 : 381-6
12. 12 Weller PH, Ingram D, Preece MA, Matthew DJ. Controlled trial of intermittent aerosol therapy with sodium 2 mercaptoethane sulphonate in cystic fibrosis. Thorax 1980 ; 35 : 42-6
13. 13 Taylor RF, Gaya H, Hodson ME. Pseudomonas cepacia: pulmonary infection in patients with cystic fibrosis. Pediatr Pulmunol 1991 ; (suppl 9) : 251
14. 14 Ratjen F, Wonne R, Posselt HG, Stover B, Hofmann D, Bender SW, A double-blind placebo-controlled trial with oral ambroxol and acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985 ; 144 : 374-8
15. 15 Caramia G, Gagliardini R, Ruffini E, Osimani P, Nobilini A. The management of cystic fibrosis with carboxycysteine lysine salt: single-blind comparative study with ambroxol hydrochloride. J. Int Med Res 1995 ; 23 : 284-93
16. 16 Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Resp J 1995 ; 8 : 1786-91
17. 17 Shah PL, Scott SF, Knight RA, Webber P, Hodson ME. Sputum sol phase tobramycin levels following treatment with recombinant human DNase I in vitro. Congrès de l'American Thoracic Society, Boston, 1994
18. 18 Davies J, Trindade M, Wallis C, Rosenthal M, Bush A. Audit of the effects of rhDNase in children with cystic fibrosis. Eur Resp J 1995 ; (suppl 19) : 512s
19. 19 Zach MS. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems. Thorax 1996 ; 51 : 750-5
20. 20 Shah PL, Scott SF, Knight RA. Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996 ; 9 : 531-4
21. 21 Rochat T, Dayer Pastore F, Schlegel-Haueter SE, Filthuth I, Auckenthaler R, Belli D et al. Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum. Eur Respir J 1996 ; 9 : 2200-6
22. 22 Costello CM, O'Connor CM, Finay GA, Shiels P, FitzGerald MX, Hayes JP. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. Thorax 1996 ; 51 : 619-23
23. 23 Dasgupta B, King M. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with N acetylcystein and rhDNase. Pediatr Pulmonol 1996 ; 22 : 161-6
24. 24 Dasgupta B, Tomkiewicz RP, De Sanetis GT, Boyd WA, King M. Mucolytic synergism in cystic fibrosis sputum with combined rhDNase and gelsolin treatment [Abstract]. Am J Respir Crit Care Med 1995 ; 151 : A19
25. 25 Tomkiewicz RP, Brown NE, King M. Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995 ; (suppl 12) : 236